DUBLIN--(BUSINESS WIRE)--The "Human Liver Models Market by Drug Discovery Platform (Non-alcoholic Fatty Liver Organoids, Liver-on-a-chip, 2D Models, Animal Models, 3D Bioprinting), and Region (North America, Europe, Asia Pacific, Rest of the World) - Global Forecast to 2022" report has been added to ResearchAndMarkets.com's offering.
The global human liver models market is expected to reach USD 2.56 billion by 2022 from USD 1.35 billion in 2017, at a CAGR of 13.6%
Growing focus on developing alternatives for animal testing models, significant increase in research funding and venture capital investments for the development of liver models, growing initiatives to increase awareness about liver organoids, increasing research activities on liver organoids, increasing prevalence of non-alcoholic fatty liver disease, and growing need for the early detection of drug toxicity to minimize financial losses due to late-stage drug failure are expected to drive the growth of the human liver models market. However, issues related to the incorporation of organoids into existing workflows are expected to restrain the growth of this market to a certain extent.
North America is expected to witness the highest growth during 2017 to 2022, owing to well-established pharmaceutical and biotechnology industry and increasing government spending. Furthermore, growing initiatives to increase awareness about organoids and growing incidence of NAFLD is expected to boost the market.
The key players in the global human liver models market are Emulate (US), Ascendance Bio (US), HREL (US), CN Bio (UK), Organovo (US), and Cyfuse Biomedical (Japan).
- Growing Focus on Developing Alternatives for Animal Testing Models
- Significant Increase in Research Funding and Venture Capital Investments for the Development of Liver Organoids
- Growing Initiatives to Increase Awareness About Liver Organoids
- Increasing Research Activities on Liver Organoids
- Increasing Prevalence of Non-Alcoholic Fatty Liver Disease
- Growing Need for the Early Detection of Drug Toxicity to Minimize Financial Losses Due to Late-Stage Drug Failure
- Issues Related to the Incorporation of Organoids Into Existing Workflows
- Increasing Focus on Drug Discovery Activities
- Rising Demand for Liver Transplantation
- Growing Healthcare Market in the Asia Pacific and Latin America
- Dearth of Skilled Professionals
For more information about this report visit https://www.researchandmarkets.com/research/4bw5pd/2018_human_liver?w=4